Silexion Therapeutics Corp., a Cayman Islands-based company, is currently facing a delisting process from the Nasdaq Global Market due to non-compliance with required market value standards. The company received a delisting notice after failing to rectify these deficiencies by the designated deadline of May 19, 2025. In response, Silexion has requested a hearing to appeal the delisting notice, which has temporarily stayed the process and allowed its securities to continue trading under the symbols "SLXN" and "SLXNW." As part of its strategy, Silexion plans to apply for a transfer of its listing to the Nasdaq Capital Market. The hearing date has not been specified, but the appeal process allows continued trading until the hearing occurs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.